WuXi Biologics (2269 HK) Hong Kong
Report by Entext
Biologics key play on Pharma moving to ‘Fabless’ outsourced manufacturing model - an increasing number of Biotech / Pharma companies are choosing to outsource production facilities to avoid navigating the increasingly challenging regulatory landscape on their own. By combining a CRO and CDMO business model, the result is a full-scale CRDMO providing a completely integrated suite of end-to-end pharma solutions, WuXi (and Samsung Biologics) are both in this elite category. At the end of 2021, WuXi had already secured 60 integrated projects from customers worldwide (+50% y/y). The recent share price sell-off on US sanction fears is overdone.